HeartBeam BEAT 深 沪
等待开盘 04-02 09:30:00 美东时间
1.2201
+0.000
+0.01%
华盛通- 最 高1.24
- 今 开1.22
- 成交量 14.96万股
- 最 低 1.21
- 昨 收 1.22
- 总市值 5013.13万
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 0.54
- 委 比 5.21%
- 总股本 4108.79万
- 历史最高 71.96
- 量 比 0.77
- 振 幅 2.46%
- 历史最低 0.54
- 每 手 1
- 风险率 0.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HeartBeam’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article
Austin, Texas, United States, April 1st, 2026, FinanceWire HeartBeam (NASDAQ:BE...
54分钟前
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter
MDB Capital Holdings, LLC (NASDAQ: MDBH) reported 2025 financial and operational results. Key assets include eXoZymes (NASDAQ: EXOZ), Paulex Bio, and PatentVest. eXoZymes has a $30 million valuation and advances cell-free biomanufacturing. Paulex Bio secured a $19 million seed round, targeting an IPO in September 2026. PatentVest aims to spin out as an AI-enhanced IP law firm. MDB Direct is exploring partnerships to expand reach. Financials show...
03-31 20:05
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
How Decentralized AI is Unlocking Value in Cardiac Diagnostics
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER,BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare r...
03-27 21:30
D. Boral Capital Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $5
D. Boral Capital analyst Jason Kolbert initiates coverage on HeartBeam (NASDAQ:BEAT) with a Buy rating and announces Price Target of $5.
03-27 20:20
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Reiterates Buy on HeartBeam, Maintains $5.5 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates HeartBeam (NASDAQ:BEAT) with a Buy and maintains $5.5 price target.
03-17 00:16
HeartBeam Earnings Call Balances Breakthroughs With Cash Risk
Heartbeam, Inc. (($BEAT)) has held its Q4 earnings call. Read on for the main h...
03-14 08:10
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), IN8bio (INAB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
03-13 09:10
